Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Nane C Kuznik"'
Autor:
Laura Cato, Antje Neeb, Adam Sharp, Victor Buzón, Scott B Ficarro, Linxiao Yang, Claudia Muhle-Goll, Nane C Kuznik, Ruth Riisnaes, Daniel Nava Rodrigues, Olivier Armant, Victor Gourain, Guillaume Adelmant, Emmanuel A Ntim, Thomas Westerling, David Dolling, Pasquale Rescigno, Ines Figueiredo, Friedrich Fauser, Jennifer Wu, Jaice T Rottenberg, Liubov Shatkina, Claudia Ester, Burkhard Luy, Holger Puchta, Jakob Troppmair, Nicole Jung, Stefan Bräse, Uwe Strähle, Jarrod A Marto, Gerd Ulrich Nienhaus, Bissan Al-Lazikani, Xavier Salvatella, Johann S de Bono, Andrew CB Cato, Myles Brown
Publikováno v:
eLife, Vol 6 (2017)
Targeting the activation function-1 (AF-1) domain located in the N-terminus of the androgen receptor (AR) is an attractive therapeutic alternative to the current approaches to inhibit AR action in prostate cancer (PCa). Here we show that the AR AF-1
Externí odkaz:
https://doaj.org/article/067bbc10110344e49721dcddfaabbd03
Autor:
Nane C. Kuznik, Valeria Solozobova, Irene I. Lee, Nicole Jung, Linxiao Yang, Karin Nienhaus, Emmanuel A. Ntim, Jaice T. Rottenberg, Claudia Muhle-Goll, Amrish Rajendra Kumar, Ravindra Peravali, Simone Gräßle, Victor Gourain, Célia Deville, Laura Cato, Antje Neeb, Marco Dilger, Christina A. Cramer von Clausbruch, Carsten Weiss, Bruno Kieffer, G. Ulrich Nienhaus, Myles Brown, Stefan Bräse, Andrew C.B. Cato
Publikováno v:
iScience
iScience, 2022, 25 (5), pp.104175. ⟨10.1016/j.isci.2022.104175⟩
iScience, 25 (5), Art.Nr. 104175
iScience, 2022, 25 (5), pp.104175. ⟨10.1016/j.isci.2022.104175⟩
iScience, 25 (5), Art.Nr. 104175
International audience; BAG1 is a family of polypeptides with a conserved C-terminal BAG domain that functions as a nucleotide exchange factor for the molecular chaperone HSP70. BAG1 proteins also control several signaling processes including proteos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::369f38ca24f54908071ef8dc4b8592bd
Autor:
Nane C Kuznik, Simone Gräßle, Andrew C.B. Cato, Qing Lei, Nicole Jung, Amina Zoubeidi, Eric M. Lewandowski, Valeria Solozobova, Ravi Shashi Nayana Munuganti, Stefan Bräse, Yu Chen
Publikováno v:
ACS chemical biology. 16(11)
All current clinically approved androgen deprivation therapies for prostate cancer target the C-terminal ligand-binding domain of the androgen receptor (AR). However, the main transactivation function of the receptor is localized at the AR N-terminal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1d8a7ed2a77a8c7d22874296fa12fcb
https://pubmed.ncbi.nlm.nih.gov/34506104
https://pubmed.ncbi.nlm.nih.gov/34506104
Publikováno v:
Journal of Molecular Endocrinology. 62:R289-R299
Androgens are important determinants of normal and malignant prostate growth. They function by binding to the C-terminal ligand-binding domain (LBD) of the androgen receptor (AR). All clinically approved AR-targeting antiandrogens for prostate cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1122ea765e6927e012241471ca4bb4fc
https://doi.org/10.1530/jme-19-0034
https://doi.org/10.1530/jme-19-0034
Autor:
Jakob Troppmair, Jennifer Wu, Jaice T. Rottenberg, Claudia Ester, Olivier Armant, Myles Brown, Claudia Muhle-Goll, Xavier Salvatella, Nane C Kuznik, Johann S. de Bono, Linxiao Yang, Gerd Ulrich Nienhaus, Adam Sharp, Victor Buzon, Scott B. Ficarro, Daniel Nava Rodrigues, Thomas Westerling, Jarrod A. Marto, Ruth Riisnaes, Ines Figueiredo, Guillaume Adelmant, Andrew C.B. Cato, Stefan Bräse, Antje Neeb, Friedrich Fauser, Uwe Strähle, Bissan Al-Lazikani, Victor Gourain, Emmanuel A. Ntim, L. Shatkina, Pasquale Rescigno, Laura Cato, David Dolling, Burkhard Luy, Nicole Jung, Holger Puchta
Publikováno v:
eLife, Vol 6 (2017)
eLife
eLife, eLife Sciences Publication, 2017, 6, ⟨10.7554/eLife.27159⟩
eLife, 6, Art.Nr. e27159
eLife
eLife, eLife Sciences Publication, 2017, 6, ⟨10.7554/eLife.27159⟩
eLife, 6, Art.Nr. e27159
Targeting the activation function-1 (AF-1) domain located in the N-terminus of the androgen receptor (AR) is an attractive therapeutic alternative to the current approaches to inhibit AR action in prostate cancer (PCa). Here we show that the AR AF-1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb279ceb4922d0c59567631e11647f67
https://elifesciences.org/articles/27159
https://elifesciences.org/articles/27159
Autor:
Myles Brown, Daniel Nava Rodrigues, Xavier Salvatella, Scott B. Ficarro, Uwe Strähle, Olivier Armant, Andrew C.B. Cato, David Dolling, Jennifer Wu, Victor Gourain, Emmanuel A. Ntim, Jaice T. Rottenberg, Pasquale Rescigno, Linxiao Yang, Laura Cato, L. Shatkina, Stefan Bräse, Jakob Troppmair, Bissan Al-Lazikani, Friedrich Fauser, Jarrod A. Marto, Antje Neeb, Claudia Muhle-Goll, Ruth Riisnaes, Adam Sharp, Victor Buzon, Thomas Westerling, Gerd Ulrich Nienhaus, Claudia Ester, Ines Figueiredo, Burkhard Luy, Guillaume Adelmant, Johann S. de Bono, Nicole Jung, Holger Puchta, Nane C Kuznik
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4d442519be5c748a2440c72ce61aaf17
https://doi.org/10.7554/elife.27159.041
https://doi.org/10.7554/elife.27159.041
Autor:
Diana Melchers, Prakash Rao, Steven P. Balk, Jonas de Tribolet-Hardy, Lewyn Li, Fatma Özgün, Shihua Sun, René Houtman, Wei Li, Takuma Uo, Robert B. Jenkins, Robert B. Den, X. Shirley Liu, Friederike J. Gruhl, Raga Vadhi, Nane C Kuznik, Adriaan B. Houtsmuller, Eric A. Klein, Bruce J. Trock, Henry W. Long, Jaice T. Rottenberg, Elai Davicioni, Laura Cato, Myles Brown, Peter S. Nelson, Stephen R. Plymate, R. Jeffrey Karnes, Nathan A. Lack, Bettina Göppert, Irene I Lee, Anna C. Groner, Ilsa Coleman, Andrew C.B. Cato, Martin E. van Royen, Tengfei Xiao
Publikováno v:
Cancer Cell
Cancer Cell, 35 (3)
Cancer Cell, 35(3), 401-+. Cell Press
Cancer Cell, 35 (3)
Cancer Cell, 35(3), 401-+. Cell Press
Androgen deprivation therapy for prostate cancer (PCa) benefits patients with early disease, but becomes ineffective as PCa progresses to a castration-resistant state (CRPC). Initially CRPC remains dependent on androgen receptor (AR) signaling, often
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a489a04be81343a891c6723bee9899aa
https://doi.org/10.1016/j.ccell.2019.01.008
https://doi.org/10.1016/j.ccell.2019.01.008